At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DNA Ginkgo Bioworks Holdings Inc.
Not Yet Opened 11-25 16:00:00 EST
8.14
+0.96
+13.37%
盘后8.19
+0.05+0.58%
19:58 EST
High8.14
Low7.36
Vol1.33M
Open7.41
D1 Closing7.18
Amplitude10.93%
Mkt Cap467.88M
Tradable Cap325.75M
Total Shares57.48M
T/O10.43M
T/O Rate3.31%
Tradable Shares40.02M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.